Beerepoot P, Lam V, Salahpour A. Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells. J Biol Chem. 2016;291:22053-22062 pubmed

Aflaki E, Borger D, Moaven N, Stubblefield B, Rogers S, Patnaik S, et al. A New Glucocerebrosidase Chaperone Reduces ?-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. J Neurosci. 2016;36:7441-52 pubmed publisher

Kim J, Tillu D, Quinn T, Mejia G, Shy A, Asiedu M, et al. Spinal dopaminergic projections control the transition to pathological pain plasticity via a D1/D5-mediated mechanism. J Neurosci. 2015;35:6307-17 pubmed publisher

Squillace M, Dodero L, Federici M, Migliarini S, Errico F, Napolitano F, et al. Dysfunctional dopaminergic neurotransmission in asocial BTBR mice. Transl Psychiatry. 2014;4:e427 pubmed publisher

Wang Y, Lee J, Oh G, Grady S, McIntosh J, Brunzell D, et al. Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function ?6* nAChRs. J Neurochem. 2014;129:315-27 pubmed publisher

Patel A, Zhu Y, Kuzhikandathil E, Banks W, Siegel A, Zalcman S. Soluble interleukin-6 receptor induces motor stereotypies and co-localizes with gp130 in regions linked to cortico-striato-thalamo-cortical circuits. PLoS ONE. 2012;7:e41623 pubmed publisher

Fox J, Sakamuru S, Huang R, Teneva N, Simmons S, Xia M, et al. High-throughput genotoxicity assay identifies antioxidants as inducers of DNA damage response and cell death. Proc Natl Acad Sci U S A. 2012;109:5423-8 pubmed publisher

Owesson White C, Roitman M, Sombers L, Belle A, Keithley R, Peele J, et al. Sources contributing to the average extracellular concentration of dopamine in the nucleus accumbens. J Neurochem. 2012;121:252-62 pubmed publisher

Navaroli D, Stevens Z, Uzelac Z, Gabriel L, King M, Lifshitz L, et al. The plasma membrane-associated GTPase Rin interacts with the dopamine transporter and is required for protein kinase C-regulated dopamine transporter trafficking. J Neurosci. 2011;31:13758-70 pubmed publisher

Hutchinson A, Deng J, Aryal D, Wetsel W, West A. Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin. Neuropsychopharmacology. 2012;37:321-37 pubmed publisher

Koprich J, Johnston T, Huot P, Reyes M, Espinosa M, Brotchie J. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. PLoS ONE. 2011;6:e17698 pubmed publisher

Koprich J, Johnston T, Reyes M, Sun X, Brotchie J. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model th. Mol Neurodegener. 2010;5:43 pubmed publisher

Abdallah L, Bonasera S, Hopf F, O DELL L, Giorgetti M, Jongsma M, et al. Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function. J Neurosci. 2009;29:8156-65 pubmed publisher

Costa C, Belcastro V, Tozzi A, Di Filippo M, Tantucci M, Siliquini S, et al. Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci. 2008;28:8040-52 pubmed publisher

Visanji N, Orsi A, Johnston T, Howson P, Dixon K, Callizot N, et al. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008;22:2488-97 pubmed publisher